pilsicainide has been researched along with Auricular Fibrillation in 56 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 9.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "Population pharmacokinetics (PK) of a sodium channel-blocking antiarrhythmic, pilsicainide, was studied using the nonlinear mixed-effects modeling technique in 91 patients with cardiac arrhythmias (80 suspected Brugada syndrome [BrS] and 11 with atrial fibrillation) who received an intravenous infusion of 10 mg of the drug." | 9.12 | Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. ( Echizen, H; Kishi, R; Kobayashi, S; Masuhara, K; Matsumoto, N; Mihara, K; Miyake, F; Nakazawa, K; Ogawa, R; Takagi, A; Takahashi, H, 2006) |
| "The present study was conducted to determine the antiarrhythmic efficacy and safety of oral pilsicainide, a class Ic antiarrhythmic drug, in patients with persistent atrial fibrillation (AF)." | 9.12 | Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II. ( Atarashi, H; Fukunami, M; Inoue, H; Kumagai, K; Okishige, K, 2006) |
| " low-dose flecainide followed by oral pilsicainide might be a promising strategy for the outpatient treatment of paroxysmal atrial fibrillation." | 9.10 | Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation. ( Kubota, I; Nagai, S; Takeishi, Y, 2003) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 9.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF)." | 9.09 | Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. ( Abe, H; Hiraki, T; Ikeda, H; Imaizumi, T; Kumagai, K; Nakashima, H; Nakashima, Y; Oginosawa, Y; Saku, K, 2000) |
| "The efficacy and safety of a single oral dose of 150-mg pilsicainide, a new class Ic antiarrhythmic drug, in converting recent-onset atrial fibrillation to sinus rhythm were evaluated in 75 patients (51 men, 24 women; age 23 to 74 years)." | 9.08 | Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. ( Atarashi, H; Hayakawa, H; Hiejima, K; Inoue, H, 1996) |
| "A single oral dose of pilsicainide, a Class Ic antiarrhythmic drug, is a widely used and highly effective therapy for termination of recent onset atrial fibrillation." | 8.80 | Ventricular pacing failure after a single oral dose of pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "Pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects were simultaneously assessed using chronic atrioventricular block dogs." | 7.75 | Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ( Iwasaki, H; Nagai, T; Nakamura, Y; Satoh, Y; Shinkai, N; Sugiyama, A; Takahara, A, 2009) |
| "It has been shown that pilsicainide terminates atrial fibrillation (AF) by pharmacologic pulmonary vein (PV) isolation." | 7.74 | Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein. ( Hamazaki, M; Hirose, M; Ohkubo, Y; Sekido, T; Takano, M; Yamada, M, 2007) |
| "A 56-year-old man with Brugada syndrome presented with ventricular fibrillation induced by administration of pilsicainide." | 7.72 | [Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 7.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "Pilsicainide hydrochloride is effective in patients with atrial fibrillation of short duration with small left atrium and rapid ventricular response." | 7.72 | [Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "This study evaluated the efficacy of long-term pilsicainide therapy to maintain sinus rhythm in patients with paroxysmal atrial fibrillation in terms of the time of onset." | 7.71 | [Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset]. ( Kimura, M; Komatsu, T; Nakamura, S; Okumura, K; Owada, S; Tomita, H; Yomogida, K, 2001) |
| "This study investigated the effects of a particular type of sodium channel blocker, pilsicainide, on spiral waves, which are a possible mechanism of atrial fibrillation, by using numerical simulation." | 7.70 | Effect of pilsicainide, a pure sodium channel blocker, on spiral waves during atrial fibrillation: theoretical analysis by numerical simulation. ( Ashihara, T; Nakazawa, K; Namba, T; Ohe, T, 1999) |
| "The purposes of this study were to measure the atrial refractory period and the conduction velocity (CV) during atrial fibrillation (AF) and to explore the antiarrhythmic mechanism of a sodium channel blocker, pilsicainide, during AF." | 7.70 | Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Takatsuki, S; Takeshita, A, 2000) |
| "A single oral dose of pilsicainide, a class 1c antiarrhythmic drug, is effective in terminating acute-onset atrial fibrillation (AF), but its effect on pacing thresholds in pacemaker patients is unknown." | 7.70 | Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "The effects of pilsicainide on vagally induced atrial fibrillation and on electrophysiological parameters were compared with those of propafenone in alpha-chloralose-anesthetized dogs." | 7.70 | Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. ( Iwasa, A; Matsunaga, T; Okumura, K; Tabuchi, T; Tayama, S; Tsuchiya, T; Tsunoda, R; Yasue, H, 1998) |
| "The antifibrillatory effect of pilsicainide, a sodium channel blocker with slow recovery kinetics, was investigated in a canine model of atrial fibrillation." | 7.70 | Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Sueyoshi, K; Takatsuki, S, 1998) |
| "An 81-year-old woman developed pilsicainide intoxication associated with dehydration." | 7.70 | Pilsicainide intoxication in a patient with dehydration. ( Matsuo, S; Ozeki, S; Utsunomiya, T; Yano, K, 1999) |
| "To inventigate the electrophysiologic effects of pilsicainide hydrochloride on atrial fibrillation, we compared atrial fibrillation threshold (AFT), right atrial effective refractory period (RAERP), and inter-atrial conduction time (Inter-ACT) before and after the administration of pilsicainide in 12 patients with lone paroxysmal atrial fibrillation." | 7.68 | [Effect of pilsicainide hydrochloride on atrial fibrillation threshold]. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Shirayama, T; Yamahara, Y, 1993) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 7.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "Pilsicainide is a newly synthesized antiarrhythmic agent with class Ic properties." | 6.69 | Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. ( Aonuma, K; Azegami, K; Igawa, M; Nishizaki, M; Okishige, K; Yamawaki, N, 2000) |
| "Pilsicainide is a class IC antiarrhythmic drug, which has a pure sodium channel blocking action with slow recovery pharmacokinetics." | 6.43 | Pilsicainide for atrial fibrillation. ( Kumagai, K; Matsumoto, N; Nakashima, H; Noguchi, H; Ogawa, M; Saku, K; Tojo, H; Yasuda, T, 2006) |
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 5.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "The present study was conducted to determine the antiarrhythmic efficacy and safety of oral pilsicainide, a class Ic antiarrhythmic drug, in patients with persistent atrial fibrillation (AF)." | 5.12 | Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II. ( Atarashi, H; Fukunami, M; Inoue, H; Kumagai, K; Okishige, K, 2006) |
| "Population pharmacokinetics (PK) of a sodium channel-blocking antiarrhythmic, pilsicainide, was studied using the nonlinear mixed-effects modeling technique in 91 patients with cardiac arrhythmias (80 suspected Brugada syndrome [BrS] and 11 with atrial fibrillation) who received an intravenous infusion of 10 mg of the drug." | 5.12 | Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. ( Echizen, H; Kishi, R; Kobayashi, S; Masuhara, K; Matsumoto, N; Mihara, K; Miyake, F; Nakazawa, K; Ogawa, R; Takagi, A; Takahashi, H, 2006) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 5.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| " low-dose flecainide followed by oral pilsicainide might be a promising strategy for the outpatient treatment of paroxysmal atrial fibrillation." | 5.10 | Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation. ( Kubota, I; Nagai, S; Takeishi, Y, 2003) |
| "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF)." | 5.09 | Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. ( Abe, H; Hiraki, T; Ikeda, H; Imaizumi, T; Kumagai, K; Nakashima, H; Nakashima, Y; Oginosawa, Y; Saku, K, 2000) |
| "The efficacy and safety of a single oral dose of 150-mg pilsicainide, a new class Ic antiarrhythmic drug, in converting recent-onset atrial fibrillation to sinus rhythm were evaluated in 75 patients (51 men, 24 women; age 23 to 74 years)." | 5.08 | Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. ( Atarashi, H; Hayakawa, H; Hiejima, K; Inoue, H, 1996) |
| "A single oral dose of pilsicainide, a Class Ic antiarrhythmic drug, is a widely used and highly effective therapy for termination of recent onset atrial fibrillation." | 4.80 | Ventricular pacing failure after a single oral dose of pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "Administration of pilsicainide, a class IC antiarrhythmic agent, caused Brugada- type ST elevation in a 66-year-old Japanese male who presented with paroxysmal atrial fibrillation (PAF), type I atrial flutter and inducible ventricular fibrillation (VF) during electrophysiological study." | 3.83 | A Novel SCN5A Mutation Associated with Drug Induced Brugada Type ECG. ( Ai, T; Horie, M; Itoh, H; Makiyama, T; Shimizu, A; Turker, I; Ueyama, T; Vatta, M, 2016) |
| "Pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects were simultaneously assessed using chronic atrioventricular block dogs." | 3.75 | Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ( Iwasaki, H; Nagai, T; Nakamura, Y; Satoh, Y; Shinkai, N; Sugiyama, A; Takahara, A, 2009) |
| "It has been shown that pilsicainide terminates atrial fibrillation (AF) by pharmacologic pulmonary vein (PV) isolation." | 3.74 | Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein. ( Hamazaki, M; Hirose, M; Ohkubo, Y; Sekido, T; Takano, M; Yamada, M, 2007) |
| "Disopyramide is thought to have an advantageous effect for atrial fibrillation (AF) associated with vagal activity because of its anticholinergic effect." | 3.73 | Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation. ( Aizawa, Y; Chinushi, M; Hirono, T; Komura, S; Sugiura, H, 2005) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 3.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "This study aimed to assess the effects of pilsicainide, a pure sodium channel blocker, on electrophysiological action and wavefront dynamics during atrial fibrillation (AF)." | 3.72 | Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. ( Ashihara, T; Hirai, H; Ikeda, T; Kawase, A; Kubota, T; Nakazawa, K; Namba, T; Sugi, K, 2003) |
| "Pilsicainide hydrochloride is effective in patients with atrial fibrillation of short duration with small left atrium and rapid ventricular response." | 3.72 | [Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "A 56-year-old man with Brugada syndrome presented with ventricular fibrillation induced by administration of pilsicainide." | 3.72 | [Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "We treated an 88-year-old man with aortic valvular stenosis/insufficiency and paroxysmal atrial fibrillation, who developed ventricular tachycardia due to pilsicainide toxicity." | 3.72 | A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. ( Funada, A; Horita, Y; Kaku, B; Kanaya, H; Kitajima, S; Matsumura, M; Satoh, T; Uno, Y; Yamazaki, T, 2004) |
| " Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions." | 3.71 | ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. ( Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sekita, G; Sumiyoshi, M; Tokano, T; Yamashita, H; Yasuda, M, 2001) |
| "This study evaluated the efficacy of long-term pilsicainide therapy to maintain sinus rhythm in patients with paroxysmal atrial fibrillation in terms of the time of onset." | 3.71 | [Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset]. ( Kimura, M; Komatsu, T; Nakamura, S; Okumura, K; Owada, S; Tomita, H; Yomogida, K, 2001) |
| " During hospitalization, atrial fibrillation developed, and oral pilsicainide was administered." | 3.71 | Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina. ( Aizawa, Y; Chinushi, M; Chinushi, Y; Toida, T, 2002) |
| "This study investigated the effects of a particular type of sodium channel blocker, pilsicainide, on spiral waves, which are a possible mechanism of atrial fibrillation, by using numerical simulation." | 3.70 | Effect of pilsicainide, a pure sodium channel blocker, on spiral waves during atrial fibrillation: theoretical analysis by numerical simulation. ( Ashihara, T; Nakazawa, K; Namba, T; Ohe, T, 1999) |
| "The purposes of this study were to measure the atrial refractory period and the conduction velocity (CV) during atrial fibrillation (AF) and to explore the antiarrhythmic mechanism of a sodium channel blocker, pilsicainide, during AF." | 3.70 | Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Takatsuki, S; Takeshita, A, 2000) |
| "The antifibrillatory effect of pilsicainide, a sodium channel blocker with slow recovery kinetics, was investigated in a canine model of atrial fibrillation." | 3.70 | Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Sueyoshi, K; Takatsuki, S, 1998) |
| "Effects of class Ic drug pilsicainide and class III drug MS-551 were determined in the canine model of atrial fibrillation (AF) induced under vagal stimulation." | 3.70 | Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart. ( Fujiki, A; Hayashi, H; Inoue, H; Tani, M; Usui, M, 1998) |
| "Increased dispersion of signal-averaged P wave duration would play an important role in generating paroxysmal atrial fibrillation and would be useful in the prediction of drug efficacy to evaluate the change in dispersion by a single administration of pilsicainide." | 3.70 | Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation. ( Asano, Y; Fukunami, M; Hoki, N; Hori, M; Kumagai, K; Ogita, H; Sanada, S; Shimonagata, T; Yamada, T, 1999) |
| "An 81-year-old woman developed pilsicainide intoxication associated with dehydration." | 3.70 | Pilsicainide intoxication in a patient with dehydration. ( Matsuo, S; Ozeki, S; Utsunomiya, T; Yano, K, 1999) |
| "A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later." | 3.70 | A case of sinus pause due to the proarrhythmia of pilsicainide. ( Abe, T; Fuse, K; Murooka, H; Saigawa, T; Susa, R; Toeda, T; Yamaguchi, Y, 2000) |
| "The effects of pilsicainide on vagally induced atrial fibrillation and on electrophysiological parameters were compared with those of propafenone in alpha-chloralose-anesthetized dogs." | 3.70 | Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. ( Iwasa, A; Matsunaga, T; Okumura, K; Tabuchi, T; Tayama, S; Tsuchiya, T; Tsunoda, R; Yasue, H, 1998) |
| "A single oral dose of pilsicainide, a class 1c antiarrhythmic drug, is effective in terminating acute-onset atrial fibrillation (AF), but its effect on pacing thresholds in pacemaker patients is unknown." | 3.70 | Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 3.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "To inventigate the electrophysiologic effects of pilsicainide hydrochloride on atrial fibrillation, we compared atrial fibrillation threshold (AFT), right atrial effective refractory period (RAERP), and inter-atrial conduction time (Inter-ACT) before and after the administration of pilsicainide in 12 patients with lone paroxysmal atrial fibrillation." | 3.68 | [Effect of pilsicainide hydrochloride on atrial fibrillation threshold]. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Shirayama, T; Yamahara, Y, 1993) |
| "Pilsicainide and bepridil were effective in 19 and 20 patients, respectively." | 2.74 | Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG. ( Fujiki, A; Fukaya, H; Hatakeyama, Y; Izumi, T; Kiryu, M; Kurokawa, S; Niwano, H; Niwano, S; Sasaki, T, 2009) |
| "Pilsicainide is a newly synthesized antiarrhythmic agent with class Ic properties." | 2.69 | Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. ( Aonuma, K; Azegami, K; Igawa, M; Nishizaki, M; Okishige, K; Yamawaki, N, 2000) |
| "Pilsicainide is a class IC antiarrhythmic drug, which has a pure sodium channel blocking action with slow recovery pharmacokinetics." | 2.43 | Pilsicainide for atrial fibrillation. ( Kumagai, K; Matsumoto, N; Nakashima, H; Noguchi, H; Ogawa, M; Saku, K; Tojo, H; Yasuda, T, 2006) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (19.64) | 18.2507 |
| 2000's | 39 (69.64) | 29.6817 |
| 2010's | 6 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Irie, M | 1 |
| Hiiro, H | 1 |
| Hamaguchi, S | 1 |
| Namekata, I | 1 |
| Tanaka, H | 1 |
| Takahara, A | 3 |
| Suzuki, S | 1 |
| Hagiwara, M | 1 |
| Nozaki, S | 1 |
| Sugiyama, A | 3 |
| Nakamura, K | 1 |
| Fukami, N | 1 |
| Yagishita, A | 1 |
| Yamauchi, Y | 1 |
| Obayashi, T | 1 |
| Hirao, K | 2 |
| Turker, I | 1 |
| Makiyama, T | 1 |
| Vatta, M | 1 |
| Itoh, H | 1 |
| Ueyama, T | 1 |
| Shimizu, A | 1 |
| Ai, T | 1 |
| Horie, M | 1 |
| Komatsu, T | 3 |
| Tachibana, H | 2 |
| Sato, Y | 2 |
| Ozawa, M | 1 |
| Ohshima, K | 1 |
| Orii, M | 1 |
| Kunigida, F | 1 |
| Nakamura, M | 2 |
| Horiuchi, D | 2 |
| Iwasa, A | 2 |
| Sasaki, K | 1 |
| Owada, S | 2 |
| Kimura, M | 2 |
| Sasaki, S | 1 |
| Okumura, K | 4 |
| Niwano, S | 5 |
| Sasaki, T | 1 |
| Kurokawa, S | 1 |
| Kiryu, M | 1 |
| Fukaya, H | 1 |
| Hatakeyama, Y | 1 |
| Niwano, H | 1 |
| Fujiki, A | 3 |
| Izumi, T | 5 |
| Iwasaki, H | 1 |
| Nakamura, Y | 2 |
| Satoh, Y | 1 |
| Nagai, T | 1 |
| Shinkai, N | 1 |
| Watanabe, I | 1 |
| Okumura, Y | 1 |
| Ohkubo, K | 1 |
| Nagashima, K | 1 |
| Sonoda, K | 1 |
| Mano, H | 1 |
| Kofune, M | 1 |
| Hirayama, A | 2 |
| Shirayama, T | 2 |
| Shiraishi, H | 1 |
| Yoshida, S | 1 |
| Matoba, Y | 1 |
| Imai, H | 1 |
| Nakagawa, M | 3 |
| Yoshida, T | 2 |
| Inuo, K | 3 |
| Saito, J | 3 |
| Kojima, J | 3 |
| Ikeda-Murakami, K | 2 |
| Hara, H | 2 |
| Kawase, A | 1 |
| Ikeda, T | 1 |
| Nakazawa, K | 3 |
| Ashihara, T | 2 |
| Namba, T | 2 |
| Kubota, T | 1 |
| Sugi, K | 1 |
| Hirai, H | 1 |
| Moriguchi, M | 2 |
| Ikeda, K | 1 |
| Nagai, S | 1 |
| Takeishi, Y | 1 |
| Kubota, I | 1 |
| Matsushita, K | 2 |
| Ishikawa, T | 2 |
| Sumita, S | 2 |
| Kobayashi, T | 2 |
| Matsumoto, K | 2 |
| Yamakawa, Y | 2 |
| Ohkusu, Y | 2 |
| Nakagawa, T | 2 |
| Nakazawa, I | 2 |
| Mochida, Y | 2 |
| Ebina, T | 2 |
| Uchino, K | 2 |
| Kimura, K | 2 |
| Umemura, S | 2 |
| Kumagai, K | 7 |
| Tojo, H | 3 |
| Noguchi, H | 3 |
| Yasuda, T | 3 |
| Ogawa, M | 3 |
| Nakashima, H | 4 |
| Zhang, B | 2 |
| Saku, K | 4 |
| Horita, Y | 1 |
| Kanaya, H | 1 |
| Uno, Y | 1 |
| Yamazaki, T | 1 |
| Kaku, B | 1 |
| Funada, A | 1 |
| Kitajima, S | 1 |
| Matsumura, M | 1 |
| Satoh, T | 1 |
| Honsho, S | 1 |
| Hashimoto, K | 1 |
| Okishige, K | 3 |
| Yamamoto, N | 1 |
| Otomo, K | 1 |
| Azegami, K | 2 |
| Isobe, M | 1 |
| Miura, S | 1 |
| Sugiura, H | 1 |
| Chinushi, M | 2 |
| Komura, S | 1 |
| Hirono, T | 1 |
| Aizawa, Y | 2 |
| Ogawa, R | 1 |
| Kishi, R | 1 |
| Mihara, K | 1 |
| Takahashi, H | 1 |
| Takagi, A | 1 |
| Matsumoto, N | 2 |
| Masuhara, K | 1 |
| Miyake, F | 1 |
| Kobayashi, S | 1 |
| Echizen, H | 1 |
| Fukunami, M | 2 |
| Atarashi, H | 2 |
| Inoue, H | 4 |
| Shinohara, T | 1 |
| Takahashi, N | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Hirose, M | 1 |
| Ohkubo, Y | 1 |
| Takano, M | 1 |
| Hamazaki, M | 1 |
| Sekido, T | 1 |
| Yamada, M | 1 |
| Imai, S | 1 |
| Saito, F | 1 |
| Takase, H | 1 |
| Enomoto, M | 1 |
| Aoyama, H | 1 |
| Yamaji, S | 1 |
| Yokoyama, K | 1 |
| Yagi, H | 1 |
| Kushiro, T | 1 |
| Ishibashi, K | 2 |
| Inoue, D | 2 |
| Omori, I | 2 |
| Inoue, M | 2 |
| Sakai, R | 2 |
| Yamahara, Y | 2 |
| Asayama, J | 2 |
| Hiejima, K | 1 |
| Hayakawa, H | 1 |
| Hayashi, H | 2 |
| Tani, M | 1 |
| Usui, M | 2 |
| Matsuo, K | 1 |
| Annoura, M | 1 |
| Ideishi, M | 1 |
| Arakawa, K | 1 |
| Tabuchi, T | 1 |
| Tsuchiya, T | 1 |
| Tsunoda, R | 1 |
| Matsunaga, T | 1 |
| Tayama, S | 1 |
| Yasue, H | 1 |
| Kanki, H | 3 |
| Mitamura, H | 3 |
| Takatsuki, S | 2 |
| Sueyoshi, K | 1 |
| Shinagawa, K | 3 |
| Sato, T | 3 |
| Ogawa, S | 3 |
| Yamada, T | 1 |
| Shimonagata, T | 1 |
| Sanada, S | 1 |
| Ogita, H | 1 |
| Asano, Y | 1 |
| Hori, M | 1 |
| Hoki, N | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Ozeki, S | 1 |
| Utsunomiya, T | 1 |
| Matsuo, S | 1 |
| Yano, K | 1 |
| Ohe, T | 1 |
| Takeshita, A | 2 |
| Tükek, T | 1 |
| Akkaya, V | 1 |
| Demirel, S | 1 |
| Sözen, AB | 1 |
| Kudat, H | 1 |
| Atilgan, D | 1 |
| Ozcan, M | 1 |
| Güven, O | 1 |
| Korkut, F | 1 |
| Kitano, Y | 1 |
| Nishizaki, M | 1 |
| Igawa, M | 1 |
| Yamawaki, N | 1 |
| Aonuma, K | 1 |
| Toeda, T | 1 |
| Susa, R | 1 |
| Saigawa, T | 1 |
| Abe, T | 1 |
| Yamaguchi, Y | 1 |
| Fuse, K | 1 |
| Murooka, H | 1 |
| Numata, T | 2 |
| Abe, H | 3 |
| Nagatomo, T | 2 |
| Kohshi, K | 2 |
| Nakashima, Y | 3 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Yamashita, H | 1 |
| Sekita, G | 1 |
| Kawano, Y | 1 |
| Mineda, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Sumiyoshi, M | 1 |
| Nakata, Y | 1 |
| Hiraki, T | 1 |
| Oginosawa, Y | 1 |
| Ikeda, H | 1 |
| Imaizumi, T | 1 |
| Conway, DS | 1 |
| Lip, GY | 1 |
| Nakamura, S | 1 |
| Tomita, H | 1 |
| Yomogida, K | 1 |
| Nattel, S | 1 |
| Kurita, Y | 1 |
| Miyoshi, S | 1 |
| Hara, M | 1 |
| Chinushi, Y | 1 |
| Toida, T | 1 |
3 reviews available for pilsicainide and Auricular Fibrillation
| Article | Year |
|---|---|
Pilsicainide for atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; | 2006 |
Ventricular pacing failure after a single oral dose of pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; | 2000 |
New antiarrhythmic agents for atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hydantoins; Imidazoles; Imidazolidines | 2001 |
13 trials available for pilsicainide and Auricular Fibrillation
| Article | Year |
|---|---|
A randomized study on the efficacy of intravenous cibenzoline and pilsicainide administered prior to electrical cardioversion in patients with lone paroxysmal and persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Electric Countershock; | 2009 |
Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cross-Over Studies; Electrocardiography | 2009 |
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Flecainide; Huma | 2003 |
Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Flecainide; Humans; | 2003 |
Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrophysiology; Female; Heart Atr | 2005 |
Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bundle-Branch Block; | 2006 |
Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cont | 2006 |
Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy.
Topics: Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Disease-F | 2006 |
Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Bepridil; Drug | 2008 |
Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; | 1996 |
Mechanism of antiarrhythmic effects of class Ic drugs in paroxysmal atrial fibrillation in man.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Arti | 1998 |
Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Admin | 2000 |
Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2000 |
40 other studies available for pilsicainide and Auricular Fibrillation
| Article | Year |
|---|---|
Involvement of the persistent Na
Topics: Action Potentials; Animals; Atrial Fibrillation; Cells, Cultured; Diastole; Guinea Pigs; Lidocaine; | 2019 |
Electrophysiological effects of an anti-influenza drug oseltamivir on the guinea-pig atrium: comparison with those of pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Atrial Function; Atrial Func | 2013 |
Altered responses to vasopressors of a patient medicated with carvedilol, pilsicainide and enalapril.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atria | 2014 |
Idiopathic ventricular fibrillation associated with early repolarization which was unmasked by a sodium channel blocker after catheter ablation of atrial fibrillation.
Topics: Atrial Fibrillation; Catheter Ablation; Electrocardiography; Female; Follow-Up Studies; Humans; Inje | 2014 |
A Novel SCN5A Mutation Associated with Drug Induced Brugada Type ECG.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Base Sequence; Brugada Syndrome; | 2016 |
Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Echocardiography; Electrophysi | 2009 |
Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs.
Topics: Administration, Cutaneous; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Bl | 2009 |
Pharmacologic atrial defibrillation by drug delivery into the temporarily occluded coronary sinus. A canine study.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Balloon Occlusion; Cardiac Pacing, Artificial; | 2012 |
Atrial fibrillation threshold predicted long-term efficacy of pharmacological treatment of patients without structural heart disease.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Disopyramide; Electrophysiologic Techn | 2002 |
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Electrocardio | 2003 |
Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria.
Topics: Acetylcholine; Animals; Atrial Fibrillation; Body Surface Potential Mapping; Dogs; Dose-Response Rel | 2003 |
Effect of pilsicainide on atrial electrophysiologic properties in the canine rapid atrial stimulation model.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; D | 2003 |
[Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Injections, | 2003 |
[Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electrophysiology; Humans; Lidocai | 2003 |
Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation.
Topics: Atrial Fibrillation; Electrophysiologic Techniques, Cardiac; Female; Humans; Infusions, Intravenous; | 2004 |
A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Creatinine; Drug Overdose; Ele | 2004 |
A simple in vivo atrial fibrillation model of rat induced by transesophageal atrial burst pacing.
Topics: Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Disease Models, Animal; Electrocardiograph | 2005 |
Long-term efficacy of hybrid pharmacologic and ablation therapy in patients with pilsicainide-induced atrial flutter.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Cathe | 2005 |
Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Dogs; E | 2005 |
Pilsicainide-induced ventricular tachycardia originating from right ventricular outflow tract.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Lidocaine; Middle Aged; Tachycardia, Ve | 2007 |
Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electr | 2007 |
[Effect of pilsicainide hydrochloride on atrial fibrillation threshold].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Lidoc | 1993 |
Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrophysiology; Female; Fleca | 1993 |
Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Dogs; Electric Stimulation; F | 1998 |
Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output; Dogs; Electric Conductivity; E | 1998 |
Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Drug Evaluation, Prec | 1998 |
Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 1999 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Pilsicainide intoxication in a patient with dehydration.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Dehydration; Electrocardiograp | 1999 |
Effect of pilsicainide, a pure sodium channel blocker, on spiral waves during atrial fibrillation: theoretical analysis by numerical simulation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Culture Techniques; Electrocardiog | 1999 |
Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; Electrocardi | 2000 |
Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart Rate; Humans; Lidoca | 2000 |
Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography | 2000 |
A case of sinus pause due to the proarrhythmia of pilsicainide.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Consciousness Disorders; El | 2000 |
Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardi | 2000 |
ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female | 2001 |
[Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Hypertensi | 2001 |
Effects of ionic remodeling on cardiac antiarrhythmic drug actions.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Down-Regulation; Electric C | 2001 |
Electropharmacologic effects of pilsicainide, a pure sodium channel blocker, on the remodeled atrium subjected to chronic rapid pacing.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; C | 2001 |
Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina.
Topics: Acetylcholine; Angina Pectoris, Variant; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2002 |